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Abstract
Background: Reactive oxygen species may be involved in epigenetic gene activation or silencing. We aimed to
identify CpG sites, at which DNA methylation is related to urinary 8-isoprostane levels (biomarker of lipid
peroxidation) and cancer or mortality outcomes. This investigation was based on a German, population-based
cohort with linkage to cancer and mortality registry data (2000–2016).
Results: Blood DNA methylation in promoter regions of 519 genes, known to be involved in pathways from
oxidative stress (OS) to cancer, was obtained at the cohort's baseline examination. Inverse associations of DNA
methylation at cg25365794 (ALOXE3) and cg08862778 (MTOR) with 8-isoprostane levels were observed in a
derivation set (n = 1000) and validated in two independent subsets of the cohort (n = 548 and n = 741). Multivariate
regression models were used to evaluate the associations of DNA methylation at the two CpG sites with lung,
colorectal, prostate, breast, and overall cancer incidence as well as CVD, cancer, and all-cause mortality. DNA methylation
at cg25365794 (ALOXE3) was inversely associated with lung and prostate cancer incidence. DNA methylation at
cg08862778 (MTOR) was associated with a 43% lower breast cancer incidence in the top vs. bottom tertile.
Conclusion: The finding for ALOXE3 may not be causal. As ALOXE3 is mainly expressed in skin tissue, the observed
association might reflect the fact that both DNA methylation at the ALOXE3 gene and urinary 8-isoprostane
concentrations depend on the level of OS in tissues. Contrarily, the finding for the MTOR gene and breast cancer is
biologically plausible because the MTOR protein plays an important role in PI3K/Akt signaling, which is a pathway related
to cancer development and cell senescence.
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Background
Oxidative stress (OS) refers to an imbalance between antiox-
idants and oxidants production in favor of the latter, result-
ing in an interruption of redox signaling and control and/or
molecular damage [1]. OS at physiological levels is termed
oxidative eustress, and maintenance of oxidative eustress is
crucial for redox regulation [2, 3]. Excessive OS, however,
can damage proteins, lipids, and nucleic acids, can contrib-
ute to the development of various age-related diseases, in-
cluding cancer [4]. The major oxidants are reactive oxygen
species (ROS), which cannot be detected directly in human
specimens because of their short half-lives [5]. Instead, ele-
vated ROS can be indirectly measured by using oxidatively
generated metabolites of proteins, lipids, or nucleic acids.
The concentration of 8-isoprostane molecules in urine, a
biomarker of lipid peroxidation, is the acknowledged gold
standard for measurement of the oxidative stress burden of
the human organism [6, 7]. Elevated 8-isoprostane levels
have been shown to be a risk factor for lung cancer [8, 9].
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Excessive ROS has been shown to be involved in the
changes of DNA methylation levels [10, 11]. For in-
stance, hydrogen peroxide acts as a nucleophile to
deprotonate the cytosine molecule at the C-5 position,
which accelerates the reaction of DNA with the
positive-charged intermediate S-adenosyl-L-methionine
in the process of DNA methylation [12]. In addition,
ROS may regulate the expression of DNA methyltrans-
ferases (DNMT), enzymes catalyzing the transfer of a
methyl group to DNA [13]. Conversely, DNA methyla-
tion alterations may regulate the expression of
OS-related genes [14]. In spite of biological plausibility,
evidence from human population-based studies on the
associations of OS biomarker concentrations with DNA
methylation of OS-related genes is sparse and the poten-
tial impact of OS-related DNA methylation alteration on
cancer development is even sparser [15, 16].
Therefore, this study aimed (i) to conduct a
gene-specific screening for CpG sites, differentially
methylated according to urinary 8-isoprostane levels,
and (ii) to investigate whether identified CpG sites are
associated with the risk of cancer or mortality.
Methods
Study population
This study is based on the ESTHER study (German: Epi-
demiologische Studie zu Chancen der Verhütung, Früher-
kennung und optimierten Therapie chronischer
Erkrankungen in der älteren Bevölkerung), which is an
ongoing prospective, population-based cohort study. De-
tails of the study design have been reported elsewhere
[17, 18]. Briefly, general practitioners, (GPs) recruited
9949 study participants aged 50 to 74 years, during a
general health check-up between 2000 and 2002 in Saar-
land, a federal state of Germany. Spot urine and whole
blood samples were collected during the health
check-up, shipped to the study center, and maintained at
− 80 °C until further processing.
Four independent subsets were selected from the ES-
THER study for epigenome-wide DNA methylation data
measurements for various projects [19] and were used
for the current analysis (Fig. 1). Subset I includes the
first 500 recruited men and the first 500 recruited
women (recruited between July and October 2000). Sub-
set II has a case-cohort design for mortality with n = 316
deaths and a random sub-cohort of n = 548. Subset III
has a case-cohort design with n = 128 breast cancer, n =
58 lung cancer, n = 23 colorectal cancer, and n = 538
mortality cases and a random sub-cohort with n = 741
subjects. Subset IV has a nested case-control design with
n = 65 incident lung cancer cases, n = 100 colorectal can-
cer cases, and n = 176 controls. In the gene-specific
screening for CpG sites, differentially methylated accord-
ing to urinary 8-isoprostane levels, subset I was used as
the derivation set and the random sub-cohorts of subset
II and III were used as two independent validation sets.
Finally, all four subsets were used to determine potential
associations of identified CpG sites with cancer (lung,
colorectal, breast, prostate, and overall cancer) and mor-
tality outcomes (cancer, CVD, and all-cause mortality).
Laboratory analyses
Urinary 8-isoprostane levels were determined by 8iso1
ELISA kit from Detroit R&D (Detroit, Michigan, USA)
with two- or fourfold dilution, depending on the concen-
trations of the marker. According to the manufacturer’s
Fig. 1 Four subsets of the German ESTHER study selected for measurement of epigenome-wide DNA methylation data, Abbreviation: BC, breast
cancer; CRC, colorectal cancer; LC, lung cancer
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manual, the specificity of the assay is 100%. For renal
function adjustment of spot urine samples, urinary cre-
atinine was determined by the kinetic Jaffe method and
8-isoprostane levels were expressed with the unit “nmol/
mmol creatinine.”
DNA methylation profiles of subset I, II, and IV were
assessed with the Infinium HumanMethylation450 Bead-
Chip (450 k) array, and DNA methylation profiles of
subset III were assessed with the Infinium Methylation
EPIC BeadChip kit that covers 850,000 CpG sites (850k)
(Illumina, San Diego, CA, USA). The assays were con-
ducted by following the manufacturer’s instruction at
the Genomics and Proteomics Core Facility of the Ger-
man Cancer Research Center, Heidelberg, Germany [20].
The methylation status of a specific CpG site was quan-
tified as a β-value ranging from 0 (no methylation) to 1
(full methylation). No background correction was done,
and data were normalized to internal controls provided
by the manufacturer. All controls were checked for in-
consistencies in each measured plate. Signals of probes
with a detection P value > 0.05 were excluded from
analysis.
Outcome ascertainment
Incident cancers until the end of 2014 were ascertained
by linkage with the Saarland Cancer Registry. According
to the 10th Revision of the International Statistical Clas-
sification of Diseases (ICD-10), cancer cases during
follow-up were defined by all ICD-10 C-codes but C44
(non-melanoma skin cancer). Colorectal, lung, breast,
and prostate cancer were defined by the ICD-10 codes
C18-C21, C34, C50, and C61, respectively.
Deaths during follow-up by the end of 2015 were
ascertained by inquiry at the residents’ registration of-
fices, and information on the vital status of 99.9% of the
cohort's participants could be obtained. Additionally,
death certificates were provided by local health author-
ities for 97.7% of those who had died. All deaths coded
with ICD-10 codes I00–I99 were considered cardiovas-
cular deaths, and cancer deaths were defined by ICD-10
codes C00–C99 and D37–D48.
Covariates assessment
Information on sociodemographic characteristics; smok-
ing behavior; physical activity; the consumption of alco-
hol, fruits, vegetables, and meat; an asthma diagnosis;
and history of cardiovascular events (stroke, myocardial
infarction, pulmonary embolism, bypass operation, or
dilatation of the coronary vessels) were obtained from a
standardized self-administered questionnaire. Height,
weight, and a history of diabetes or coronary heart dis-
ease (CHD) were assessed and documented on a stan-
dardized form by GPs during the health check-up. The
history of cancer before baseline was determined by
either self-report or record linkage with data from the
Saarland Cancer Registry, which started to record can-
cers in 1970.
Selection of CpG site candidates
To increase the statistical power, a gene-specific search
was performed with restriction to genes coding for pro-
teins that are involved in intracellular ROS generating
organelles and enzymes and signal transduction cascades
kinases/phosphatases or transcription factors that are on
pathways from increased OS to cancer development.
These proteins have been identified by our group in a
systematic literature review and reported previously [21].
Altogether, 542 genes involved in 18 pathways were
identified. We excluded 8 genes, which were not in-
cluded in the 450k array, and 15 genes, which were on
the X chromosome, leaving 519 genes for analyses. The
3811 CpG sites in the promoter regions of these 519
genes were selected for the screening in the derivation
set. The selection process of the CpG sites is illustrated
in Fig. 2, and the 519 selected genes and their pathways
are listed in Additional file 1: Table S1.
Statistical analyses
Baseline characteristics of participants of the derivation
sample and the two validation samples were expressed
as medians (interquartile ranges) or proportions, and dif-
ferences among the three samples were determined by
Wilcoxon-Mann-Whitney tests for continuous variables
and by chi-square tests for discrete variables.
In the derivation set, a mixed linear regression model
was used to assess the associations between the methyla-
tion levels of the selected 3811 CpG sites and
8-isoprostane levels. A natural logarithm transformation
of 8-isoprostane levels was employed to ensure normal
distribution. The model was adjusted for age (continu-
ously), sex (male/female), leukocyte composition using
Houseman’s algorithm [22] (6 continuous variables), al-
cohol consumption (continuously), body mass index
(BMI, continuously), physical activity (inactive, low,
medium, or high), fruit consumption (</≥ once/day),
vegetables consumption (</≥ once/day), meat consump-
tion (</≥ once/day), smoking status (with seven categor-
ies, as shown in Table 1), history of cancer (yes/no),
cardiovascular diseases (yes/no), diabetes (yes/no), and
asthma (yes/no). Batch-specific variations of the DNA
methylation assay were modeled as random effects.
The top 10 CpG sites with the lowest P values for the
association with 8-isoprostane levels in the derivation
set were selected, and the same linear mixed regression
model analyses were repeated in the two validation sets.
Obtained β-coefficients and standard errors were subse-
quently pooled by fixed effects meta-analysis. To ac-
count for multiple testing, only CpG sites with a false
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discovery rate (FDR) < 0.05 were considered to be statis-
tically significant and selected for analyses with cancer
and mortality outcomes.
To explore the associations between DNA methylation
at the selected CpG sites and cancer incidences (overall,
lung, colorectal, breast, and prostate cancer) as well as
mortality outcomes (all-cause, cancer-specific and car-
diovascular disease-specific mortality), Cox regression,
weighted Cox regression [20], and logistic regression
models were used for cohort (subset I and random
sub-cohorts of subset II and II), case-cohort (subset II
and III), and nested case-control study designs (subset
IV), respectively. Hazard ratios (HRs) with correspond-
ing 95% confidence intervals (95% CIs) were estimated
in subset I–III, and odds ratios (ORs) with 95% CIs were
assessed in the subset IV and results were pooled by
fixed effects meta-analysis. Subjects with a history of the
specific cancer of interest were excluded. In a sensitivity
analysis, also cancer cases that occurred in the first
2 years of follow-up (potentially undiagnosed cancers at
baseline) were excluded, but overall, the results did not
change (data not shown). The regression models were
adjusted for age, sex, leukocyte composition, and
batches. Additional potential confounders, to be adjusted
for in the regression models, needed to be statistically
significantly associated with DNA methylation levels at
the selected CpG site (P < 0.05). The potential con-
founders were identified among all variables shown in
Table 1 in general linear models. Methylation intensities
were included into the models either as tertiles to test
for non-linear associations (bottom tertiles defined as
the reference category) or as continuous variables to test
for linear associations.
Multiple imputation was applied to adequately deal
with missing values, and five data sets were imputed.
The variables for the imputation model were those
shown in Table 1. No variable had more than 10% miss-
ing information. The multiple imputation assumption
(values missing at random) was examined, and individ-
uals with complete data did not differ from those with
incomplete data (data not shown). All statistical tests
were conducted with the Statistical Analysis System
(SAS, version 9.4, Cary, NC, USA).
Results
Table 1 presents the baseline characteristics of partici-
pants in derivation set and the two validation sets. Sub-
jects were on average 62 years old. Because of different
sampling strategies, the derivation set includes equal
numbers of men and women and the validation sets
have a higher proportion of women than men. The dif-
ferent sex distribution resulted in some statistically sig-
nificant differences in baseline characteristics
(categorized BMI, asthma, 8-isoprostane levels,
leukocyte composition), but otherwise, the characteris-
tics of the three samples were comparable.
From the 3811 CpG sites in the promoter regions of
the 519 selected genes, information on the top 10 CpG
sites associated with 8-isoprostane concentrations in the
derivation set are shown in Additional file 1: Table S2 (P
value ≤ 7.05 × 10−4; FDR ≤ 0.227) and the pooled results
from the two validation sets are shown in Table 2. DNA
methylation levels at three CpG sites were statistically
significantly associated with 8-isoprostane concentra-
tions after FDR correction: cg25365794 [Arachidonate
LipOXygEnase 3 (ALOXE3) gene], cg01009697 [Neuro-
trophic Receptor Tyrosine Kinase 2 (NTRK2) gene], and
cg08862778 [Mechanistic target of rapamycin kinase
(MTOR) gene]. However, the methylation levels at
cg01009697 were positively associated with
8-isoprostane levels in the deviation set (Additional file 1:
Table S2) and inversely associated with 8-isoprostane
Fig. 2 Flow chart of CpG sites selection, Abbreviation: FDR, false
discovery rate
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Table 1 Baseline characteristics of study participants used for the gene-specific screening for CpG sites, differentially methylated
according to urinary 8-isoprostane levels
Characteristics Derivation set (n = 1000) 1st validation set (n = 548) 2nd validation set (n = 741) P value#
Age (year, median, IQR) 62 (57–67) 62 (57–67) 62 (56–67) 0.30
Sex (n, %) < 0.001
Female 500 (50.0) 324 (61.0) 415 (56.0)
Male 500 (50.0) 224 (39.0) 326 (44.0)
Education (n, %) 0.95
< 9 years 737 (73.7) 411 (75.0) 548 (74.0)
9–11 years 155 (15.5) 85 (15.5) 115 (15.5)
> 12 years 108 (10.8) 52 (9.5) 78 (10.5)
Smoking status (n, %) 0.19
Never smoker 481 (48.1) 257 (46.9) 363 (49.0)
Former smoker who quitted > 20 years ago 124 (12.4) 74 (13.5) 112 (15.1)
Former smoker who quitted 5 to < 20 years ago 149 (14.9) 83 (15.2) 100 (13.5)
Former smoker who quitted 0 to < 5 years ago 60 (6.0) 29 (5.3) 31 (4.2)
Current smoker smoking 0 to < 15 g tobacco/day 84 (8.4) 49 (8.9) 60 (8.1)
Current smoker smoking 15 to < 30 g tobacco/day 97 (9.7) 49 (8.9) 60 (8.1)
Current smoker smoking > 30 g tobacco/day 5 (0.5) 7 (1.3) 15 (2.0)
Alcohol consumption (g/day, median, IQR) † 6.0 (0–14.4) 5.6 (0–12.6) 4.8 (0–13.7) 0.80
Physical activity (n, %) ‡ 0.17
Inactive 204 (20.4) 114 (20.8) 157 (21.2)
Sedentary 438 (43.8) 270 (49.3) 343 (46.3)
Vigorously active 358 (35.8) 164 (39.9) 241 (32.5)
BMI (kg/m2, median, IQR) 27.4 (25.0–30.1) 27.1 (24.5–30.1) 27.2 (24.9–30.1) 0.39
Categorized BMI (n, %) < 0.001
< 25 kg/m2 251 (25.1) 167 (30.5) 195 (26.3)
25 to < 30 kg/m2 483 (48.3) 235 (42.9) 350 (47.2)
≥ 30 kg/m2 266 (26.6) 146 (26.6) 196 (26.5)
Dietary factors (n, %)
Fruit consumption, < once/day 391 (39.2) 192 (35.0) 287 (38.7) 0.26
Vegetable consumption, < once/day 656 (65.6) 341 (62.2) 461 (62.2) 0.25
Meat consumption, ≥ once/day 349 (34.9) 178 (31.5) 247 (33.3) 0.59
Leukocyte composition (mean, SD) ┼
CD8+ T cells 0.07 (0.05–0.10) 0.09 (0.07–0.12) 0.06 (0.04–0.09) < 0.001
CD4+ T cells 0.16 (0.12–0.20) 0.17 (0.13–0.20) 0.16 (0.12–0.20) 0.01
NK cells 0.91 (0.07–0.12) 0.09 (0.07–0.12) 0.10 (0.07–0.13) 0.18
B cells 0.06 (0.05–0.07) 0.07 (0.06–0.08) 0.06 (0.04–0.07) < 0.001
Monocytes 0.10 (0.09–0.11) 0.10 (0.09–0.11) 0.07 (0.06–0.08) < 0.001
Granulocytes 0.55 (0.48–0.60) 0.54 (0.47–0.59) 0.56 (0.50–0.62) < 0.001
8-isoprostane (nmol/mmol creatinine, median, IQR) 0.19 (0.13–0.26) 0.21 (0.16–0.27) 0.21 (0.16–0.28) < 0.001
Prevalent cancer cases (n, %) 75 (7.5) 32 (6.0) 57 (7.7) 0.46
Prevalent CVD cases (n, %) ^ 218 (21.8) 107 (20.2) 137 (18.5) 0.24
Prevalent diabetes cases (n, %) 155 (15.5) 89 (16.8) 108 (14.6) 0.64
Prevalent asthma cases (n, %) 74 (7.4) 23 (4.3) 49 (6.6) 0.19
Abbreviations: BMI body mass index, CVD cardiovascular disease, IQR interquartile range
#Differences in baseline characteristics among the three groups were assessed with a Wilcoxon signed-rank test for continuous variables and a chi-square test for
categorical variables
†The consumption of alcohol was calculated by the following equation: 1 bottle of beer = 11.88 g ethanol, 1 glass of wine = 22.0 g ethanol, 1 shot of liquor = 6.4 g ethanol
‡Definition of inactive: < 1 h of physical activity/week. Definition of medium or high physical activity: ≥ 2 h of vigorous and ≥ 2 h of light physical activity/week. Definition
of low physical activity: all other amounts of activity not categorized as “inactive” or “medium or high”
┼Estimated by the Houseman algorithm
^Cardiovascular disease at baseline is a composite variable of either coronary heart disease or history of one or more cardiovascular event (i.e., stroke, myocardial
infarction, pulmonary embolism, bypass operation, or dilatation of the coronary vessels)
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levels in the validation sets (Table 2), which means that
the results in the derivation set were not confirmed in
the validation sets. Therefore, cg01009697 was excluded
from further analyses. The distribution of the methyla-
tion levels of the selected two CpG sites in the three
subsets is shown in Additional file 1: Figure S1. The lin-
ear inverse associations of the methylation levels at the
two selected CpG sites with 8-isoprostane levels are add-
itionally shown graphically in a scatter plot in Add-
itional file 1: Figure S2. The explained variance of
8-isoprostane levels by DNA methylation at both CpG
sites was rather low (R2 ranged from 0.0015 to 0.0148 in
the three subsets). None of the baseline characteristics
of the study participants was statistically significantly as-
sociated with DNA methylation at the two selected CpG
sites (data not shown).
The identified two CpG sites were carried forward to
the testing for associations of OS-related DNA methyla-
tion with cancer and mortality outcomes (Table 3). Every
one standard deviation (SD) increase in DNA methyla-
tion at cg25365794 (ALOXE3 gene) resulted in a 19% de-
crease in incidence of lung cancer (HR (95%) 0.81 (0.66,
0.99)). Furthermore, an inverse association of
cg25365794 (ALOXE3 gene) with prostate cancer was
observed (HR (95% CI) per 1 SD increase: 0.78 (0.60,
1.03)), but only the comparison of the middle and the
bottom tertile was statistically significant (HR (95% CI)
0.47 (0.24, 0.92)). DNA methylation at cg08862778
(MTOR gene) was statistically inversely associated with
breast cancer (top tertile vs. bottom tertile, HR (95% CI)
0.57 (0.33, 0.97)).
Discussion
In summary, based on this gene-promoter-specific
screening analysis in three independent subsets of the
ESTHER cohort, DNA methylation at cg25365794
(ALOXE3 gene) and cg08862778 (MTOR gene) where
inversely associated with 8-isoprostane levels. In further
analysis, association of DNA methylation at the two se-
lected CpG sites with cancer or mortality outcomes was
explored in four subsets has been meta-analyzed. DNA
methylation at cg25365794 (ALOXE3 gene) was inversely
associated with lung and prostate cancer. Moreover, an
inverse association was found between DNA methylation
at cg08862778 (MTOR gene) and breast cancer.
The ALOXE3 gene encodes arachidonate lipoxygenase
3, which converts polyunsaturated fatty acid hydroperox-
ides via an alkoxyl radical intermediate to epoxyalcohols
and ketons [23]. These products play an indispensable
role in formation of the water-impermeable barrier of
the outer epidermis [24]. As ALOXE3 is mainly
expressed in skin tissue and to a lesser extent in several
other tissues [25], a direct link to 8-isoprostane concen-
trations in urine is rather unlikely. The observed signifi-
cant correlation between DNA methylation at the
ALOXE3 gene and 8-isoprostane concentrations might
reflect the fact that both depend on the level of OS in
tissues. Taken together, the observed associations of
DNA methylation at the ALOXE3 gene and lung and
prostate cancer development might not be causal. How-
ever, the currently missing biological plausibility may be
found by future studies. To our knowledge, only one
population-based study linked ALOXE3 gene and cancer
so far and showed that men with mutations in the
ALOXE3 gene can have a dysfunctional epidermis bar-
rier and may have an increased risk for prostate cancer
if exposed to pesticides [26].
The MTOR gene encodes a serine-threonine protein
kinase (mTOR) serving as a core component of two
multi-protein complexes, mTOR complex 1 (mTORC1)
Table 2 Meta-analysis of the associations of DNA methylation at the top 10 CpG sites associated with 8-isoprostane concentrations
in the two validation sets
Identified CpG sites Gene name Pathways ß-coefficient SE P value FDR
cg25365794 ALOXE3 Prostaglandin 2 biosynthesis and metabolism − 4.540 1.338 0.001 0.010
cg01009697 NTRK2 PI3K/Akt and MAPK signaling pathways − 2.266 0.780 0.004 0.020
cg08862778 MTOR Various pathways, such as PI3K/Akt − 3.326 1.270 0.009 0.030
cg27095527 PPARG Nuclear receptors in lipid metabolism and toxicity − 0.694 0.695 0.318 0.694
cg05784862 KSR1 RET signaling and MAPK signaling pathways − 0.224 0.295 0.447 0.694
cg19623877 MYB Response to elevated platelet cytosolic Ca2+ 0.427 0.604 0.480 0.694
cg06671842 PTPN5 PAK and MAPK signaling pathways − 0.307 0.440 0.486 0.694
cg19192120 SSH3 Regulation of actin cytoskeleton and cytoskeletal signaling pathways − 0.094 0.321 0.769 0.898
cg02168857 EPHA7 EPHA forward signaling pathway − 0.117 0.480 0.808 0.898
cg15093079 EPHA6 EPHA forward signaling pathway 0.025 0.659 0.969 0.969
Abbreviations: Akt protein kinase B, ALOXE3 arachidonate lipoxygenase 3, EPHA6 EPH receptor A6, EPHA7 EPH receptor A7, FDR false discovery rate, KSR1 Kinase
suppressor of Ras 1, MAPK mitogen-activated protein kinase, MTOR mechanistic target of rapamycin kinase, MYB MYB proto-oncogene, transcription factor, NTRK2
neurotrophic receptor tyrosine kinase 2, PI3K phosphoinositide 3-kinase, PPARG peroxisome proliferator activated receptor gamma, PTPN5 protein tyrosine
phosphatase, non-receptor type 5, SE standard error, SSH3 slingshot protein phosphatase 3
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Table 3 Associations of oxidative stress-related DNA methylation at the selected CpG sites with cancer incidences and mortality
outcomes
Outcomes cg25365794 cg08862778
HR (95% CI)* HR (95% CI)*
Overall incident cancer#
Tertile 1 Ref. Ref.
Tertile 2 0.77 (0.59, 1.01) 0.93 (0.71, 1.21)
Tertile 3 0.90 (0.68, 1.18) 0.84 (0.62, 1.12)
Increase per 1 SD 0.98 (0.87, 1.10) 0.99 (0.87, 1.12)
Incident lung cancer†
Tertile 1 Ref. Ref.
Tertile 2 0.73 (0.46, 1.16) 0.90 (0.57, 1.41)
Tertile 3 0.78 (0.48, 1.27) 0.67 (0.40, 1.11)
Increase per 1 SD 0.81 (0.66, 0.99) 0.94 (0.77, 1.15)
Incident colorectal cancer†
Tertile 1 Ref. Ref.
Tertile 2 0.72 (0.43, 1.19) 1.07 (0.65, 1.76)
Tertile 3 0.83 (0.50, 1.40) 1.46 (0.88, 2.44)
Increase per 1 SD 0.98 (0.79, 1.21) 1.16 (0.96, 1.41)
Incident breast cancer‡ (in female participants)
Tertile 1 Ref. Ref.
Tertile 2 0.91 (0.55, 1.51) 0.67 (0.40, 1.11)
Tertile 3 0.91 (0.50, 1.65) 0.57 (0.33, 0.97)
Increase per 1 SD 0.90 (0.70, 1.16) 0.84 (0.63, 1.11)
Incident prostate cancer#(in male participants)
Tertile 1 Ref. Ref.
Tertile 2 0.47 (0.24, 0.92) 0.97 (0.49, 1.92)
Tertile 3 0.68 (0.37, 1.24) 1.11 (0.51, 2.42)
Increase per 1 SD 0.78 (0.60, 1.03) 1.15 (0.82, 1.62)
All-cause mortality┼
Tertile 1 Ref. Ref.
Tertile 2 0.90 (0.74, 1.11) 0.99 (0.80, 1.22)
Tertile 3 1.14 (0.93, 1.41) 1.17 (0.93, 1.47)
Increase per 1 SD 1.03 (0.94, 1.12) 1.08 (0.98, 1.18)
Cancer mortality┼
Tertile 1 Ref. Ref.
Tertile 2 0.91 (0.69, 1.20) 0.87 (0.66, 1.16)
Tertile 3 0.87 (0.65, 1.16) 0.97 (0.71, 1.31)
Increase per 1 SD 0.92 (0.81, 1.05) 1.06 (0.94, 1.20)
CVD mortality┼
Tertile 1 Ref. Ref.
Tertile 2 0.87 (0.65, 1.16) 1.04 (0.77, 1.40)
Tertile 3 1.23 (0.92, 1.66) 1.28 (0.93, 1.75)
Increase per 1 SD 1.04 (0.92, 1.17) 1.08 (0.95, 1.22)
Numbers printed in italics: statistically significantly different from 1 (P < 0.05)
Abbreviations: CI confidence interval, CVD cardiovascular disease, HR hazard ratio, SD standard deviation
*The Cox regression model was adjusted for age, sex, batch, and leukocyte distribution
#Meta-analyzed results from subset I (cohort design, n = 1000), sub-cohort of subset II (cohort design, n = 548), and sub-cohort of subset III (cohort design, n = 741)
†Meta-analyzed results from subset I (cohort design, n = 1000), sub-cohort of subset II (cohort design, n = 548), subset III (case-cohort design, n = 741; sub-cohort, n = 80
lung cancer cases, n = 37 colorectal cancer cases), and subset IV (nested case-control design, n = 65 lung cancer cases, n = 100 colorectal cancer cases, n = 176 controls)
‡Meta-analyzed results from subset I (cohort design, n = 1000), sub-cohort of subset II (cohort design, n = 548), and subset III (case-cohort design, n = 741; sub-cohort,
n = 128 breast cancer cases)
┼Meta-analyzed results from subset I (cohort design, n = 1000), subset II (case-cohort design, n = 548; sub-cohort, n = 316 all-cause mortality, n = 128 cancer mortality,
n = 104 CVD mortality), and subset III (case-cohort design, n = 741; sub-cohort, n = 538 all-cause mortality, n = 209 cancer mortality, n = 181 CVD mortality)
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and mTOR complex 2 (mTORC2), which respond to
stressors, including DNA damage, nutrients, and oxida-
tive stress [27, 28]. Hydrogen peroxide, a major product
of oxidative stress, can activate the PI3K/AKT/mTOR
signaling pathway by inhibiting its suppressor, PTEN
(phosphatase and tensin homolog) [21]. The PI3K/Akt
axis is involved in the regulation of the mTORC1. Acti-
vation of PI3K leads to phosphorylation and activation
of Akt, which subsequently activates mTORC1 [29].
Over-activation of mTORC1 leads to widespread but be-
nign tumor formation [28]. The mTORC2 protein acts
as a tyrosine kinase and phosphorylates Akt, which has a
function in maintaining cancer cell survival [30, 31].
Therefore, the PI3K/Akt/mTOR signaling is a target for
the treatment of cancer. For instance, everolimus is an
mTOR inhibitor and was approved for breast cancer
treatment [32]. Supporting our findings, Tang et al. ob-
served that a CpG site located in the regulatory associ-
ated protein of MTOR complex 1 (RPTOR) gene, which
is an activator of mTOR, was hypomethylated in breast
cancer patients compared to healthy controls [33].
Therefore, our finding adds evidence to a pathway of
ROS-mediated PI3K/AKT/mTOR activation to breast
cancer development. This pathway might be in part con-
trolled by DNA demethylation in the promoter region of
the MTOR gene.
To our knowledge, our study is the first gene-specific
study, which screened for associations of DNA methyla-
tion with 8-isoprostane levels. There is only one other
similar study, which used a different biomarker of OS
(derivatives of reactive oxygen metabolites (d-ROM))
and had a much smaller sample size (n = 99 in derivation
set, n = 142 in validation set) [15]. In this
epigenome-wide screening study, DNA methylation at
cg10342304 (nucleoredoxin (NXN) gene) was associated
with derivatives of reactive oxygen metabolites (d-ROM)
and, moreover, significantly associated with overall can-
cer incidence [15]. A further study that measured DNA
methylation in four oxidative stress-related genes identi-
fied a significant association of DNA methylation at one
site in the promotor region of the 8-oxoguanine DNA
glycosylase (OGG1) gene with overall cancer incidence
and prostate cancer incidence [16]. However, the results
were neither corrected for multiple testing nor validated
in another sample. The choice of different OS bio-
markers in these two studies may explain why we did
not observe associations with DNA methylation at the
NXN and the OGG1 gene.
Our analysis has a number of strengths. First, detailed
information on a broad range of covariates enabled us to
control for potential confounding as far as possible. Sec-
ond, its prospective design for the cancer outcomes pre-
cluded reverse causality. Third, usage of almost complete
cancer registry and mortality follow-up data excluded
misclassification and non-response bias. Fourth, we per-
formed the screening with OS and cancer-related genes
identified in a systematic review. This hypothesis-based
gene-specific approach has a higher statistical power than
an epigenome-wide screening approach. Lastly, the
8-isoprostane molecule has proven long-term stability in
frozen urine samples and is a reliable biomarker for OS
[34]. Nevertheless, DNA methylation at cg25365794
(ALOXE3 gene) and cg08862778 (MTOR gene) may be use-
ful in the future as biomarkers for long-term OS exposure
because they may have a higher intra-individual stability
time than urinary concentrations of 8-isoprostane.
However, several limitations of our analysis should be
taken into account when interpreting the results. First,
DNA methylation levels vary across tissue types [35] and
whole blood DNA methylation can only reflect the over-
all methylation levels in leukocytes. Second, screening
and validation sets were obtained from the same study
population. Other studies are needed to corroborate our
findings for the ALOXE3 and MTOR genes, to conduct
gene expression analyses in multiple CpG sites in the
promotor/CpG islands of these genes, and to find fur-
ther CpG sites with OS-related DNA methylation. This
may provide further insights into the mechanisms of
OS-related cancer development and aging.
Conclusion
In this population-based cohort, DNA methylation at
two CpG sites was associated with urinary 8-isoprostane
levels. DNA methylation alterations at the identified
CpG sites were associated with specific cancer outcomes.
While the association between urinary 8-isoprostane
levels and DNA methylation at the ALOXE3 gene may
not be causal, the findings for MTOR gene methylation
are biologically plausible. There might be a pathway of
ROS-mediated PI3K/AKT/mTOR activation to breast
cancer that is in part controlled by DNA demethylation
in the promoter region of the MTOR gene.
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